“…In mouse models of vaginal infection, some Saps (mostly Sap2 and Sap6, or Sap5, depending on the model [33,39]), appear to be responsible for the expression of key immunopathogenic markers of landmark inflammatory events. This includes polymorphonuclear (PMN) cell infiltration and production of pro-inflammatory cytokines, such as IL-1β and IL-18, via the activation of inflammasome-mediated caspase-1 and possibly other caspases [41]. The use of individual or collective subfamily SAP knockout strains, human anti-Sap Fragment antigen binding (Fab), and whole transcriptome analyses has shown that inflammation in vaginal disease can be dampened either downstream, by pharmacological inhibition of NLRP3 inflammasome and blockade of IL-1β receptor, or upstream, by specifically affecting Sap production or activity by anti-Sap antibodies or pepstatin A, without affecting the infectious fungus burden [38,39] (Fig 3).…”